Related Experiment Video
Updated: Jun 18, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Neoadjuvant targeted therapy versus targeted combined with chemotherapy for resectable EGFR-mutant non-small cell
Weipeng Shao1, Zhan Liu1, Bobo Li1
1Department of Thoracic Surgical Ward II, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Background:
This study aimed to assess the role and effect of neoadjuvant targeted therapy (TT) versus targeted combined with chemotherapy (TC) for resectable EGFR-mutant non-small cell lung cancer (NSCLC).
Methods:
Between March 2021 and June 2023, 20 patients with stage IA3-IIIB NSCLC were enrolled in the study. Eleven patients received EGFR-TKIs in the TT group, while nine patients received EGFR-TKIs and two cycles of cisplatin-based doublet chemotherapy (TC group). We compare the differences between the two groups through the following variables, including age, sex, surgical approach, postoperative complications, neoadjuvant therapy adverse events, complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), objective response rate (ORR), major pathologic response (MPR), and pathologic complete response (pCR).
Results:
Patients were predominantly female (75%) and never-smokers (95%). The average age was 59.2 years (range 46-79 years). Fifty-five percent harbored an exon 19 EGFR mutation and 45% an exon 21 mutation. The average targeted drug dosing time was 2.91 ± 1.7 (range 1-6) months in the TT group and 3.56 ± 3.54 (range 1-12) months in the TC group (P=0.598). The most common side effects were rash and diarrhea. No grade 5 events with neoadjuvant therapy were observed. The rate of R0 resection was 100% in all patients. Among the 11 patients in the TT group, 6 achieved a PR and 5 had SD, resulting in an ORR of 54.5%. Among the 9 patients in the TC group, 6 had PR and the remaining 3 had SD, resulting in an ORR of 66.6%. one patient (11.1%) in the TC group achieved pCR, while no patients in the TT group achieved pCR (P = 0.142). Two patients (18.2%) in the TT group reached MPR, and 2 patients (22.2%) in the TC group reached MPR (P = 0.257). The overall clinical downstage rate is 60%. Only 9 (45%) cases of yield clinical TNM (ycTNM) were consistent with yield pathologic TNM (ypTNM).
Conclusion:
Results from this retrospective controlled research indicate that the neoadjuvant TT group is likely to be more effective outcomes and has safer profile in patients with EGFR-positive NSCLC than the neoadjuvant TC group. However, our results need to be validated in a multicenter, large sample prospective study.
Insights
Neoadjuvant targeted therapy (TT) showed promising outcomes and a safer profile for resectable EGFR-mutant non-small cell lung cancer (NSCLC) compared to targeted therapy combined with chemotherapy (TC). Further validation in larger studies is recommended.
Area of Science:
- Oncology
- Thoracic Surgery
- Pharmacology
Background:
- Non-small cell lung cancer (NSCLC) with EGFR mutations presents unique treatment challenges.
- Neoadjuvant therapy is increasingly explored to improve surgical outcomes in resectable NSCLC.
- Targeted therapy (TT) and combination therapy (TC) are potential neoadjuvant strategies.
Purpose of the Study:
- To compare the efficacy and safety of neoadjuvant TT versus TC in patients with resectable EGFR-mutant NSCLC.
- To evaluate treatment response, pathologic outcomes, and adverse events associated with each neoadjuvant approach.
Main Methods:
- A retrospective study involving 20 patients with stage IA3-IIIB NSCLC.
- Patients received either TT (EGFR-TKIs) or TC (EGFR-TKIs plus chemotherapy).
- Outcomes assessed included objective response rate (ORR), major pathologic response (MPR), and pathologic complete response (pCR).
Main Results:
- Both TT and TC groups achieved 100% R0 resection rates.
- ORR was 54.5% for TT and 66.6% for TC.
- No grade 5 adverse events were reported; rash and diarrhea were most common.
Conclusions:
- Neoadjuvant TT may offer a safer profile with comparable efficacy to TC for EGFR-mutant NSCLC.
- Further large-scale prospective studies are necessary to confirm these findings.
- The study highlights the potential of tailored neoadjuvant strategies in NSCLC management.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...